Aurobindo Pharma rises on getting USFDA`s final nod to manufacture, market Perampanel tablets
Aurobindo Pharma is currently trading at Rs. 1681.40, up by 6.40 points or 0.38% from its previous closing of Rs. 1675.00 on the BSE.
The scrip opened at Rs. 1739.95 and has touched a high and low of Rs. 1739.95 and Rs. 1,664.15 respectively. So far 5845 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1739.95 on 5-Oct-2026 and a 52 week low of Rs. 1066.00 on 08-Oct-2025.
Last one week high and low of the scrip stood at Rs. 1,739.95 and Rs. 1649.35 respectively. The current market cap of the company is Rs. 96007.56 crore.
The promoters holding in the company stood at 51.88 % while Institutions and Non-Institutions held 41.48 % and 6.64 % respectively.
Aurobindo Pharma has received receipt of final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg, which are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fycompa Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg, of Catalyst Pharmaceuticals, Inc.
The product will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of the company and will be launched in Q3FY27. The approved product has an estimated market size of $67 million for the twelve months ending August 2026. The company now has a total of 599 ANDA approvals (574 final approvals and 25 tentative approvals) from USFDA.
Perampanel Tablets are (i) indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older and (ii) indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
